New tools for the study of Alzheimer's disease: What are biomarkers and morphometric markers teaching us?

Neuroscientist

Volumn 17, Issue 5, 2011, Pages 592-605

  Fjell, Anders M ^a,b   Walhovd, Kristine B ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Alzheimer's disease; amyloid; cognition; CSF biomarkers; early diagnosis; morphometry; MRI

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; GLUTAMATE RECEPTOR; PRESENILIN; TAU PROTEIN;

ALZHEIMER DISEASE; AMNESIA; AMYLOID PLAQUE; ARTICLE; BRAIN ATROPHY; CEREBROSPINAL FLUID; CINGULATE GYRUS; DIFFUSION TENSOR IMAGING; DISEASE COURSE; ENTORHINAL CORTEX; HUMAN; MORPHOMETRICS; NEUROFIBRILLARY TANGLE; NEUROMONITORING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SENILE PLAQUE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BIOLOGICAL MARKERS; BRAIN; HUMANS; MAGNETIC RESONANCE IMAGING;

EID: 80054043057     PISSN: 10738584     EISSN: 10894098     Source Type: Journal    
DOI: 10.1177/1073858410392586     Document Type: Article

References (77)

1. Andersson C, Blennow K, Almkvist O, Andreasen N, Engfeldt P, Johansson SE. Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Neurobiol Aging. 2008 ; 29: 1466-73
2. Apostolova LG, Hwang KS, Andrawis JP, Green AE, Babakchanian S, Morra JH. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging. 2010 ; 31: 1284-303
3. Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology. 1992 ; 42: 1681-8
4. Ashe KH, Zahs KR. Probing the biology of Alzheimer's disease in mice. Neuron. 2010 ; 66: 631-45
5. Atiya M, Hyman BT, Albert MS, Killiany R. Structural magnetic resonance imaging in established and prodromal Alzheimer disease: a review. Alzheimer Dis Assoc Disord. 2003 ; 17: 177-95 (Pubitemid 37205710)
6. Bakkour A, Morris JC, Dickerson BC. The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology. 2009 ; 72: 1048-55
7. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx. 2004 ; 1: 213-25 (Pubitemid 46589353)
8. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006 ; 368: 387-403 (Pubitemid 44108123)
9. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003 ; 2: 605-13 (Pubitemid 37162569)
10. Braak H, de Vos RA, Jansen EN, Bratzke H, Braak E. Neuropathological hallmarks of Alzheimer's and Parkinson's diseases. Prog Brain Res. 1998 ; 117: 267-85 (Pubitemid 28530695)
11. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007 ; 3: 186-91 (Pubitemid 46825511)
12. Buckner RL, Wheeler ME. The cognitive neuroscience of remembering. Nat Rev Neurosci. 2001 ; 2: 624-34 (Pubitemid 33674054)
13. Buerger K, Alafuzoff I, Ewers M, Pirttila T, Zinkowski R, Hampel H. No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2007 ; 130: e82
14. Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2006 ; 129: 3035-41 (Pubitemid 44684523)
15. Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah AR. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol. 2009 ; 66: 1557-62
16. Cavanna AE, Trimble MR. The precuneus: a review of its functional anatomy and behavioural correlates. Brain. 2006 ; 129: 564-83 (Pubitemid 43278220)
17. Chou YY, Lepore N, Avedissian C, Madsen SK, Parikshak N, Hua X. Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment & elderly controls. Neuroimage. 2009 ; 46: 394-410
18. Davatzikos C, Xu F, An Y, Fan Y, Resnick SM. Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index. Brain. 2009 ; 132: 2026-35
19. de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging. 2006 ; 27: 394-401 (Pubitemid 43185324)
20. de Leon MJ, George AE, Stylopoulos LA, Smith G, Miller DC. Early marker for Alzheimer's disease: the atrophic hippocampus. Lancet. 1989 ; 2: 672-3 (Pubitemid 19220242)
21. Driscoll I, Davatzikos C, An Y, Wu X, Shen D, Kraut M, Resnick SM. Longitudinal pattern of regional brain volume change differentiates normal aging from MCI. Neurology. 2009 ; 72: 1906-13
22. Du AT, Schuff N, Kramer JH, Rosen HJ, Gorno-Tempini ML, Rankin K. Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia. Brain. 2007 ; 130: 1159-66 (Pubitemid 47355598)
23. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007 ; 6: 734-46 (Pubitemid 47058377)
24. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006 ; 59: 512-9 (Pubitemid 43358072)
25. Fan Y, Batmanghelich N, Clark CM, Davatzikos C. Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline. Neuroimage. 2008 ; 39: 1731-43 (Pubitemid 351179414)
26. Fennema-Notestine C, Hagler DJ, McEvoy LK, Fleisher AS, Wu EH, Karow DS, Dale AM. Structural MRI biomarkers for preclinical and mild Alzheimer's disease. Hum Brain Mapp. 2009 ; 30: 3238-53
27. Fjell AM, Walhovd KB, Amlien I, Bjornerud A, Reinvang I, Gjerstad L. Morphometric changes in the episodic memory network and tau pathologic features correlate with memory performance in patients with mild cognitive impairment. AJNR Am J Neuroradiol. 2008 ; 29: 1183-9 (Pubitemid 351954891)
28. Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D. One-year brain atrophy evident in healthy aging. J Neurosci. 2009 ; 29: 15223-31
29. Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J Neurosci. 2010a ; 30: 2088-101
30. Fjell AM, Amlien IK, Westlye LT, Stenset V, Fladby T, Skinningsrud A. CSF biomarker pathology correlates with a medial temporo-parietal network affected by very mild to moderate Alzheimer's disease but not a fronto-striatal network affected by healthy aging. Neuroimage. 2010b ; 49: 1820-30
31. Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D. Brain atrophy in healthy aging is related to CSF levels of Abeta1-42. Cereb Cortex. 2010c ; 20: 2069-79
32. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008 ; 29: 1456-65
33. Fyhn M, Molden S, Witter MP, Moser EI, Moser MB. Spatial representation in the entorhinal cortex. Science. 2004 ; 305: 1258-64 (Pubitemid 39129224)
34. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science. 2006 ; 314: 777-81 (Pubitemid 44706636)
35. Hampel H, Burger K, Pruessner JC, Zinkowski R, DeBernardis J, Kerkan D. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol. 2005 ; 62: 770-3 (Pubitemid 40656092)
36. Hesse C, Rosengren L, Vanmechelen E, Vanderstichele H, Jensen C, Davidsson P, Blennow K. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimers Dis. 2000 ; 2: 199-206 (Pubitemid 32095607)
37. Holland D, Brewer JB, Hagler DJ, Fenema-Notestine C, Dale AM. Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A. 2009 ; 106: 20954-9
38. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008 ; 372: 216-23 (Pubitemid 351978111)
39. Horaitis O, Talbot CC, Phommarinh M, Phillips KM, Cotton RG. A database of locus-specific databases. Nat Genet. 2007 ; 39: 425
40. Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol. 2010 ; 119: 669-78
41. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008 ; 131: 1630-45 (Pubitemid 351806448)
42. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010 ; 9: 119-28
43. Jack CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009 ; 132: 1355-65
44. Jonsson L, Eriksdotter Jonhagen M, Kilander L, Soininen H, Hallikainen M, Waldemar G. Determinants of costs of care for patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2006 ; 21: 449-59
45. Kohannim O, Hua X, Hibar DP, Lee S, Chou YY, Toga AW. Boosting power for clinical trials using classifiers based on multiple biomarkers. Neurobiol Aging. 2010 ; 31: 1429-42
46. Lee HG, Zhu X, Nunomura A, Perry G, Smith MA. Amyloid beta: the alternate hypothesis. Curr Alzheimer Res. 2006 ; 3: 75-80
47. Leow AD, Yanovsky I, Parikshak N, Hua X, Lee S, Toga AW. Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage. 2009 ; 45: 645-55
48. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006 ; 440: 352-7
49. McDonald CR, McEvoy LK, Gharapetian L, Fennema-Notestine C, Hagler DJ, Holland D. Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. Neurology. 2009 ; 73: 457-65
50. McEvoy LK, Fennema-Notestine C, Roddey JC, Hagler DJ, Holland D, Karow DS. Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology. 2009 ; 251: 195-205
51. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL. Alzheimer's disease neuroimaging initiative: episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009 ; 132: 1310-23
52. Neve RL. Alzheimer's disease sends the wrong signals: a perspective. Amyloid. 2008 ; 15: 1-4 (Pubitemid 351238491)
53. Okonkwo OC, Alosco ML, Griffith HR, Mielke MM, Shaw LM, Trojanowski JQ, Tremont G. Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease. Arch Neurol. 2010 ; 67: 688-96
54. Pimplikar SW. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int J Biochem Cell Biol. 2009 ; 41: 1261-8
55. Portelius E, Zetterberg H, Gobom J, Andreasson U, Blennow K. Targeted proteomics in Alzheimer's disease: focus on amyloid-beta. Expert Rev Proteomics. 2008 ; 5: 225-37 (Pubitemid 351670927)
56. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999 ; 45: 358-68 (Pubitemid 29120041)
57. Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol. 2009 ; 21: 117-28
58. Radde R, Duma C, Goedert M, Jucker M. The value of incomplete mouse models of Alzheimer's disease. Eur J Nucl Med Mol Imaging 35 Suppl. 2008 ; 1: S70-4
59. Salat DH, Tuch DS, van der Kouwe AJ, Greve DN, Pappu V, Lee SY. White matter pathology isolates the hippocampal formation in Alzheimer's disease. Neurobiol Aging. 2008 ; 31: 244-56
60. Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004 ; 42: 23-36 (Pubitemid 38456965)
61. Schmand B, Huizenga HM, van Gool WA. Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease. Psychol Med. 2010 ; 40: 135-45
62. Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain. 2009 ; 132: 1067-77
63. Scoville WB, Milner B. Loss of recent memory after bilateral hippocampal lesions. J Neurol Neurosurg Psychiatry. 1957 ; 20: 11-21
64. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008 ; 14: 837-42
65. Sluimer JD, Bouwman FH, Vrenken H, Blankenstein MA, Barkhof F, van der Flier WM, Scheltens P. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging. 2010 ; 31: 758-64
66. Spires-Jones TL, Stoothoff WH, de Calignon A, Jones PB, Hyman BT. Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci. 2009 ; 32: 150-9
67. Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003 ; 60: 652-6 (Pubitemid 36246085)
68. Tisserand DJ, Pruessner JC, Sanz Arigita EJ, van Boxtel MP, Evans AC, Jolles J, Uylings HB. Regional frontal cortical volumes decrease differentially in aging: an MRI study to compare volumetric approaches and voxel-based morphometry. Neuroimage. 2002 ; 17: 657-69 (Pubitemid 35317001)
69. Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement. 2010 ; 6: 230-8
70. Vann SD, Aggleton JP, Maguire EA. What does the retrosplenial cortex do?. Nat Rev Neurosci. 2009 ; 10: 792-802
71. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology. 2009a ; 73: 294-301
72. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology. 2009b ; 73: 287-93
73. Walhovd KB, Fjell AM, Brewer J, McEvoy LK, Fennema-Notestine C, Hagler DJ. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am J Neuroradiol. 2010 ; 31: 347-54
74. Walhovd KB, Westlye LT, Amlien I, Espeseth T, Reinvang I, Raz N. Consistent neuroanatomical age-related volume differences across multiple samples. Neurobiol Aging. 2009 ;:
75. Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology. 2010 ; 74: 1531-7
76. Westlye LT, Walhovd KB, Dale AM, Bjornerud A, Due-Tonnessen P, Engvig A. Differentiating maturational and aging-related changes of the cerebral cortex by use of thickness and signal intensity. Neuroimage. 2010 ; 52: 172-85
77. Zetterberg H, Blennow K, Hanse E. Amyloid beta and APP as biomarkers for Alzheimer's disease. Exp Gerontol. 2010 ; 45: 23-9